Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA)
2017; Lippincott Williams & Wilkins; Volume: 135; Issue: 16 Linguagem: Inglês
10.1161/circulationaha.117.027666
ISSN1524-4539
AutoresSivabaskari Pasupathy, Rosanna Tavella, John F. Beltrame,
Tópico(s)Takotsubo Cardiomyopathy and Associated Phenomena
ResumoHomeCirculationVol. 135, No. 16Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA) Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessEditorialPDF/EPUBMyocardial Infarction With Nonobstructive Coronary Arteries (MINOCA)The Past, Present, and Future Management Sivabaskari Pasupathy, BSc(Hons), PhD, Rosanna Tavella, BSc(Hons), PhD and John F. Beltrame, BSc, BMBS, PhD Sivabaskari PasupathySivabaskari Pasupathy From Discipline of Medicine, University of Adelaide, Australia (S.P., R.T., J.F.B.); Cardiology Department, Central Adelaide Local Health Network, Adelaide, Australia (S.P., R.T., J.F.B.); and Cardiology Department, Lyell McEwin Hospital, Adelaide, Australia (J.F.B.). , Rosanna TavellaRosanna Tavella From Discipline of Medicine, University of Adelaide, Australia (S.P., R.T., J.F.B.); Cardiology Department, Central Adelaide Local Health Network, Adelaide, Australia (S.P., R.T., J.F.B.); and Cardiology Department, Lyell McEwin Hospital, Adelaide, Australia (J.F.B.). and John F. BeltrameJohn F. Beltrame From Discipline of Medicine, University of Adelaide, Australia (S.P., R.T., J.F.B.); Cardiology Department, Central Adelaide Local Health Network, Adelaide, Australia (S.P., R.T., J.F.B.); and Cardiology Department, Lyell McEwin Hospital, Adelaide, Australia (J.F.B.). Originally published18 Apr 2017https://doi.org/10.1161/CIRCULATIONAHA.117.027666Circulation. 2017;135:1490–1493Article, see p 1481Myocardial infarction with nonobstructive coronary arteries (MINOCA) is clinically defined by the presence of the universal acute myocardial infarction (AMI) criteria, absence of obstructive coronary artery disease (≥50% stenosis), and no overt cause for the clinical presentation at the time of angiography (eg, classic features for takotsubo cardiomyopathy).1 With the more frequent contemporary use of coronary angiography in AMI, clinicians have been regularly confronted with this puzzling problem and seeking guidance in its management. An article by Lindahl et al2 in this issue of Circulation represents a major step forward in MINOCA and thereby warrants taking stock of the past, present, and future management strategies of this intriguing condition.The PastThe pioneering early angiography studies of DeWood et al demonstrated that ST-segment–elevation myocardial infarction was often associated with an occluded epicardial artery, but this occurred less frequently in non–ST-segment–elevation myocardial infarction, although in both conditions obstructive coronary artery disease was evident in >95% of patients.3 These findings underscored the importance of the underlying atherothrombotic process and provided the impetus for major advances in AMI management over the next 35 years. However, when angiography failed to reveal the presence of obstructive atheroma or thrombosis in patients with clinical criteria for ST-segment–elevation myocardial infarction, some clinicians labeled these patients as having a false-positive ST-segment–elevation myocardial infarction diagnosis.4 Such a label implies that an AMI has not occurred (despite the clinical presentation) and therefore no further diagnostic investigation or cardiac therapy is required.To avoid such diagnostic complacency, the diagnosis of MINOCA was coined5 with an emphasis on investigating these patients to identify the underlying cause of their AMI presentation. Providing a label for this clinical syndrome was the first key step in improving the management of these patients because MINOCA was promoted as a working diagnosis that necessitated the identification of an underlying cause, much the same as a diagnosis of heart failure or anemia requires such action.3 This was further emphasized in the first position statement on this disorder,1 although it has yet to be incorporated into AMI guidelines.The PresentWith the concept of MINOCA established, the next key step in its management was to identify the potential underlying causes and optimal diagnostic pathway in evaluating these patients. Potential underlying mechanisms include coronary causes such as coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli, and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies; and noncardiac causes, for example, pulmonary embolism. Multiple diagnostic pathways have been proposed to evaluate patients with MINOCA,1,6,7 with early cardiac magnetic resonance imaging (CMRI) being a central investigation in most pathways because of its ability to detect common causes.8 Indeed, recent reports claimed that CMRI identifies the underlying cause in as many as 87% of patients with MINOCA.9 Other investigations include provocative spasm testing, screening for thrombophilia disorders, and intravascular ultrasound1; however, routine screening for pulmonary embolism with computed tomographic pulmonary angiography is of very limited value.10Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9),3 with comparative studies consistently demonstrating a better prognosis than for those who experience AMI associated with obstructive coronary artery disease.3,11 Moreover, Kang et al12 confirmed that 12-month major adverse cardiac events (MACE; death and myocardial infarction) in patients with MINOCA were comparable to patients with AMI associated with single- or double-vessel coronary artery disease. In addition to these MACE outcomes, Grodzinsky et al13 demonstrated that 25% of patients with MINOCA continued to experience angina 12 months after AMI, which is equivalent to the rate in those with AMI associated with obstructive coronary artery disease.Considering the guarded prognosis of patients with MINOCA, the next beckoning question is, What therapies should be recommended? Currently, there are no randomized trials addressing this question. However, the article by Lindahl et al12 published in this issue of Circulation provides the first insight into potential long-term medical therapy in the management of MINOCA. Using the strength of the internationally acclaimed SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapy), the authors have garnered a large cohort of consecutive patients with MINOCA (n=9466) and used a stratified propensity score analysis approach to examine the effect of 4 conventional postinfarct therapies (statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and dual antiplatelet therapy) on long-term MACE (defined as all-cause mortality, AMI hospitalization, ischemic stroke, and heart failure). A secondary objective was to examine the impact of these therapies on bleeding events. The key study findings include (1) a reduced hazard ratio of MACE with the use of statins (hazard ratio=0.77; 95% confidence interval, 0.68–0.87) or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (hazard ratio=0.82; 95% confidence interval, 0.73–0.93) with a trend observed in β-blocker therapy (hazard ratio=0.86; 95% confidence interval, 0.74–1.01) and (2) no associated benefit with the use of dual antiplatelet therapy but a trend toward an increased bleeding rate.Although a nonrandomized study with important limitations (see below), this study is a game changer because for the first time there are data (rather than opinion) on potential beneficial therapies to reduce MACE in patients with MINOCA. Accordingly, clinicians can no longer dismiss patients with MINOCA as having false-positive AMIs but need to consider the potential benefit of statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in these patients. Hence, the study is a major step forward in the recognition and management of MINOCA.As indicated by the authors, important limitations in this retrospective cohort study are the heterogeneous nature of MINOCA and that no investigations to identify the underlying causes were routinely performed in this cohort. Although clinically overt causes were excluded because study inclusion was based on discharge diagnosis, less conspicuous presentations may have been overlooked. For example, in a meta-analysis of 5 studies involving 556 patients with MINOCA, Tornvall et al14 demonstrated that 33% had CMRI evidence of myocarditis despite fulfilling the diagnostic criteria for AMI. Hence, in the above analysis, up to one third of the patients treated with statin or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers may have had myocarditis, for which the benefits of these therapies are unclear. If CMRI were performed on all patients and the therapies were targeted to those patients with MINOCA with evidence of true myocardial infarction, perhaps the observed benefits would have been even greater.The FutureThe Lindahl et al12 study has provided direction for the next key step in the management of MINOCA, namely a multicenter randomized controlled trial confirming the benefits of these conventional therapies on MACE. With a prospectively designed trial, there is an opportunity for a more targeted therapeutic approach by identifying the underlying cause with screening investigations. Confirmation of the above findings would mandate the evaluation of patients with MINOCA and the initiation of secondary prevention therapies. This would not only be paradigm shifting in relation to the treatment of MINOCA but also provoke a re-evaluation of the mechanisms for these beneficial agents in the context of minimal or no atherosclerotic disease.This trial design also highlights an evolving problem in MINOCA publications relating to the generic and specific uses of the term. In the position paper,1 the term MINOCA is used in an all-encompassing context to include all patients fulfilling the universal criteria for AMI without obstructive coronary artery disease and no clinically overt cause for the presentation at the time of coronary angiography. As described above, this should initiate further investigation such as CMRI to identify the underlying cause. However, the term MINOCA is also being used in a more specific context to exclusively describe patients with evidence of ischemia-related myocardial necrosis (as the name implies). This dual interpretation of the MINOCA term will cause confusion in the future, especially if specific therapies are identified for ischemic-related MINOCA. Thus, a revision of the nomenclature is warranted, and perhaps the generic form of the term should be replaced with a broader label (eg, troponin-positive nonobstructive coronary arteries [TP-NOCA]) that encompasses patients with coronary disorders resulting in ischemic necrosis (ie, MINOCA), as well as structural myocardial disorders and noncardiac disorders11 (Figure). Future position papers should address this important issue in this rapidly evolving field.Download figureDownload PowerPointFigure. Troponin-positive nonobstructive coronary arteries. MINOCA indicates myocardial infarction with nonobstructive coronary arteries.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Circulation is available at http://circ.ahajournals.org.Correspondence to: John F. Beltrame, BSc, BMBS, PhD, Discipline of Medicine, The Queen Elizabeth Hospital, University of Adelaide, 28 Woodville Road, Woodville South, Adelaide, South Australia, Australia 5011. E-mail [email protected]References1. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, De Caterina R, Zimarino M, Roffi M, Kjeldsen K, Atar D, Kaski JC, Sechtem U, Tornvall P; Working Group on Cardiovascular Pharmacotherapy. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries.Eur Heart J. 2017; 38:143–153. doi: 10.1093/eurheartj/ehw149.MedlineGoogle Scholar2. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld A, Gard A, Jernberg T. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with non obstructive coronary artery disease.Circulation. 2017; 135:1481–1489. doi: 10.1161/CIRCULATIONAHA.116.026336.LinkGoogle Scholar3. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.Circulation. 2015; 131:861–870. doi: 10.1161/CIRCULATIONAHA.114.011201.LinkGoogle Scholar4. McCabe JM, Armstrong EJ, Kulkarni A, Hoffmayer KS, Bhave PD, Garg S, Patel A, MacGregor JS, Hsue P, Stein JC, Kinlay S, Ganz P. Prevalence and factors associated with false-positive ST-segment elevation myocardial infarction diagnoses at primary percutaneous coronary intervention–capable centers: a report from the Activate-SF registry.Arch Intern Med. 2012; 172:864–871. doi: 10.1001/archinternmed.2012.945.CrossrefMedlineGoogle Scholar5. Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA).J Intern Med. 2013; 273:182–185. doi: 10.1111/j.1365-2796.2012.02591.x.CrossrefMedlineGoogle Scholar6. Agewall S, Eurenius L, Hofman-Bang C , Malmqvist K, Frick M, Jernberg T, Tornvall P. Myocardial infarction with angiographically normal coronary arteries.Atherosclerosis. 2011; 219:10–14. doi: 10.1016/j.atherosclerosis.2011.04.036.CrossrefMedlineGoogle Scholar7. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management.Eur Heart J. 2015; 36:475–481. doi: 10.1093/eurheartj/ehu469.CrossrefMedlineGoogle Scholar8. Arai AE. False positive or true positive troponin in patients presenting with chest pain but "normal" coronary arteries: lessons from cardiac MRI.Eur Heart J. 2007; 28:1175–1177. doi: 10.1093/eurheartj/ehl567.CrossrefMedlineGoogle Scholar9. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan AD, Grover S, Smith E, Mazhar J, Bridgman C, Ganesan AN, Selvanayagam JB. Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging.Eur Heart J Cardiovasc Imaging. 2016; 17:1146–1152. doi: 10.1093/ehjci/jev289.CrossrefMedlineGoogle Scholar10. Collste O, Sörensson P, Frick M, Agewall S, Daniel M, Henareh L, Ekenbäck C, Eurenius L, Guiron C, Jernberg T, Hofman-Bang C, Malmqvist K, Nagy E, Arheden H, Tornvall P. Myocardial infarction with normal coronary arteries is common and associated with normal findings on cardiovascular magnetic resonance imaging: results from the Stockholm Myocardial Infarction with Normal Coronaries study.J Intern Med. 2013; 273:189–196. doi: 10.1111/j.1365-2796.2012.02567.x.CrossrefMedlineGoogle Scholar11. Pasupathy S, Tavella R, Beltrame JF. The what, when, who, why, how and where of myocardial infarction with non-obstructive coronary arteries (MINOCA).Circ J. 2016; 80:11–16. doi: 10.1253/circj.CJ-15-1096.CrossrefMedlineGoogle Scholar12. Kang WY, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ, Choi DH, Cho MC, Kim CJ, Seung KB, Chung WS, Jang YS, Rha SW, Bae JH, Cho JG, Park SJ; Korea Acute Myocardial Infarction Registry Investigators. Are patients with angiographically near-normal coronary arteries who present as acute myocardial infarction actually safe?Int J Cardiol. 2011; 146:207–212. doi: 10.1016/j.ijcard.2009.07.001.CrossrefMedlineGoogle Scholar13. Grodzinsky A, Arnold SV, Gosch K, Spertus JA, Foody JM, Beltrame J, Maddox TM, Parashar S, Kosiborod M. Angina frequency after acute myocardial infarction in patients without obstructive coronary artery disease.Eur Heart J Qual Care Clin Outcomes. 2015; 1:92–99. doi: 10.1093/ehjqcco/qcv014.CrossrefMedlineGoogle Scholar14. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, Leurent G, Meneveau N, Montaudon M, Perez-David E, Sörensson P, Agewall S. Myocarditis or "true" infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: a meta-analysis of individual patient data.Atherosclerosis. 2015; 241:87–91. doi: 10.1016/j.atherosclerosis.2015.04.816.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Gardarsdottir H, Sigurdsson M, Andersen K and Gudmundsdottir I (2022) Long-term survival of Icelandic women following acute myocardial infarction, Scandinavian Cardiovascular Journal, 10.1080/14017431.2022.2075561, 56:1, (114-120), Online publication date: 31-Dec-2022. Ko H, Kim T, Lee H, Byun J and Choo K (2022) Coronary artery spasm due to acute myocarditis in an adolescent: a case report, BMC Pediatrics, 10.1186/s12887-022-03354-7, 22:1, Online publication date: 1-Dec-2022. Raparelli V, Nocella C, Proietti M, Romiti G, Corica B, Bartimoccia S, Stefanini L, Lenzi A, Viceconte N, Tanzilli G, Cammisotto V, Pilote L, Cangemi R, Basili S, Carnevale R, Tiberti C, Panimolle F, Isidori A, Giannetta E, Venneri M, Napoleone L, Novo M, Quattrino S, Ceccarelli S, Anastasiadou E, Megiorni F, Marchese C, Mangieri E, Tanzilli G, Viceconte N, Barillà F, Gaudio C, Paravati V, Tellan G, Ettorre E, Servello A, Miraldi F, Moretti A, Tanzilli A, Mazzonna P, Al Kindy S, Iorio R, Di Iorio M, Petriello G, Gioffrè L, Indolfi E, Pero G, Cocco N, Iannetta L, Giannuzzi S, Centaro E, Sergi S, Pignatelli P, Amoroso D, Bartimoccia S, Talerico G, Minisola S, Morelli S, Fraioli A, Nocchi S, Fontana M, Toriello F, Ruscio E, Todisco T, Sperduti N, Santangelo G, Visioli G, Vano M, Borgi M, Antonini L, Robuffo S, Tucci C, Rossoni A, Spugnardi V, Vernile A, Santoliquido M, Santori V, Tosti G, Recchia F, Morricone F, Scacciavillani R, Lipari A, Zito A, Testa F, Ricci G, Vellucci I, Vincenti M, Pietropaolo S, Scala C, Rubini N, Tomassi M, Rozzi G, Santomenna F, Cantelmi C, Costanzo G, Rumbolà L, Giarrizzo S, Sapia C, Scotti B, Toni D, Falcou A, Pilote L, Kaur A, Azizi Z, Vestri A, Ferroni P, Crescioli C, Antinozzi C, Pignataro F, Bellini T, Zuliani G, Passaro A, Gloria B, Cutini A, Capatti E, Dalla Nora E, Di Vece F, D'Amuri A, Romagnoli T, Luciani F, Polastri M, Violi A, Fortunato V, Bella A, Manfredini R, De Giorgi A, Fabbian F, Carnevale R, Nocella C, Catalano C, Carbone I, Galea N, Bertazzoni G, Suppa M, Rosa A, Galardo G, Alessandroni M, Coppola A, Palladino M, Illuminati G, Consorti F, Mariani P, Neri F, Salis P, Segatori A, Tellini L and Costabile G (2022) Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project, Journal of Endocrinological Investigation, 10.1007/s40618-022-01771-0, 45:7, (1367-1377), Online publication date: 1-Jul-2022. Chicote-Álvarez E, Fuster-Cabré M and Ruiz de la Cuesta-López M (2022) Vasoespasmo de arteria coronaria derecha en paciente ingresado por neumonía bilateral por infección por SARS-CoV-2: reporte de caso, Acta Colombiana de Cuidado Intensivo, 10.1016/j.acci.2021.04.006, 22, (S114-S116), Online publication date: 1-Jun-2022. Markousis‐Mavrogenis G, Bacopoulou F, Mavragani C, Voulgari P, Kolovou G, Kitas G, Chrousos G and Mavrogeni S (2022) Coronary microvascular disease: The "Meeting Point" of Cardiology, Rheumatology and Endocrinology, European Journal of Clinical Investigation, 10.1111/eci.13737, 52:5, Online publication date: 1-May-2022. Magnani G, Bricoli S, Ardissino M, Maglietta G, Nelson A, Malagoli Tagliazucchi G, Disisto C, Celli P, Ferrario M, Canosi U, Cernetti C, Negri F, Merlini P, Tubaro M, Berzuini C, Manzalini C, Ignone G, Campana C, Moschini L, Ponte E, Pozzi R, Fetiveau R, Buratti S, Paraboschi E, Asselta R, Botti A, Tuttolomondo D, Barocelli F, Biagi A, Bonura R, Moccetti T, Crocamo A, Benatti G, Paoli G, Solinas E, Notarangelo M, Moscarella E, Calabrò P, Duga S, Niccoli G and Ardissino D (2022) Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA), International Journal of Cardiology, 10.1016/j.ijcard.2022.02.015, 354, (7-13), Online publication date: 1-May-2022. Minhas A, Michos E and Hays A (2022) Is Vasospastic Coronary Disease More Common Than We Realize?, JACC: Case Reports, 10.1016/j.jaccas.2022.01.014, 4:5, (298-300), Online publication date: 1-Mar-2022. Rafiudeen R, Barlis P, White H and van Gaal W (2022) Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin, European Cardiology Review, 10.15420/ecr.2021.42, 17 Liang K, Nakou E, Del Buono M, Montone R, D'Amario D and Bucciarelli-Ducci C (2022) The Role of Cardiac Magnetic Resonance in Myocardial Infarction and Non-obstructive Coronary Arteries, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.821067, 8 Gudenkauf B, Hays A, Tamis‐Holland J, Trost J, Ambinder D, Wu K, Arbab‐Zadeh A, Blumenthal R and Sharma G (2021) Role of Multimodality Imaging in the Assessment of Myocardial Infarction With Nonobstructive Coronary Arteries: Beyond Conventional Coronary Angiography, Journal of the American Heart Association, 11:1, Online publication date: 4-Jan-2022. Dees D, Rahimi F, Amann M, Nührenberg T, Löffelhardt N, Schmitz R, Valina C, Neumann F and Hochholzer W (2021) Prevalence and Causes of Myocardial Infarction with Non-Obstructive Coronary Arteries in a Contemporary Cohort of Patients with Suspected Myocardial Infarction, Journal of Clinical Medicine, 10.3390/jcm10215188, 10:21, (5188) Tayal B, Freeman P, Ericsson F, Kragholm K, Andersen N, Hagendorff A, Aaroe J, Sogaard P and Zaremba T (2020) Characterisation of patients with and without cardiac magnetic resonance imaging abnormalities presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA), Acta Cardiologica, 10.1080/00015385.2020.1785134, 76:7, (760-768), Online publication date: 2-Nov-2021. Pasupathy S, Lindahl B, Litwin P, Tavella R, Williams M, Air T, Zeitz C, Smilowitz N, Reynolds H, Eggers K, Nordenskjöld A, Barr P, Jernberg T, Marfella R, Bainey K, Sodoon Alzuhairi K, Johnston N, Kerr A and Beltrame J (2021) Survival in Patients With Suspected Myocardial Infarction With Nonobstructive Coronary Arteries: A Comprehensive Systematic Review and Meta-Analysis From the MINOCA Global Collaboration, Circulation: Cardiovascular Quality and Outcomes, 14:11, Online publication date: 1-Nov-2021. Ya'qoub L, Elgendy I and Pepine C (2021) Syndrome of Nonobstructive Coronary Artery Diseases: A Comprehensive Overview of Open Artery Ischemia, The American Journal of Medicine, 10.1016/j.amjmed.2021.06.038, 134:11, (1321-1329), Online publication date: 1-Nov-2021. Ishii M, Seki T, Kaikita K, Sakamoto K, Nakai M, Sumita Y, Nishimura K, Miyamoto Y, Noguchi T, Yasuda S, Kanaoka K, Terasaki S, Saito Y, Tsutsui H, Komuro I, Ogawa H, Tsujita K and Kawakami K (2020) Association of short-term exposure to air pollution with myocardial infarction with and without obstructive coronary artery disease, European Journal of Preventive Cardiology, 10.1177/2047487320904641, 28:13, (1435-1444), Online publication date: 25-Oct-2021. Pelliccia F, Marzilli M, Boden W and Camici P (2021) Why the Term MINOCA Does Not Provide Conceptual Clarity for Actionable Decision-Making in Patients with Myocardial Infarction with No Obstructive Coronary Artery Disease, Journal of Clinical Medicine, 10.3390/jcm10204630, 10:20, (4630) Pasupathy S, Lindahl B, Tavella R, Nordenskjöld A, Zeitz C, Arstall M, Worthley M, Neil C, Singh K, Turner S, Rajwani A, Mooney J and Beltrame J (2021) Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment for Post Infarct Angina in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries: A MINOCA-BAT Sub Study Rationale and Design, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.717526, 8 Gurevich K, Urakov A, Fisher E, Abzalilov T, Khairzamanova K, Yagudin T and Samorodov A (2021) Possibilities of pharmacological correction of reperfusion injury of ischemic myocardium (review), Reviews on Clinical Pharmacology and Drug Therapy, 10.17816/RCF193259-267, 19:3, (259-267) Tu T, Li J, Fang Z, Hu X, Tang J, Zhao Y, Tang L and Zhou S In-Hospital Cardiac Arrest after Emotional Stress in a Patient Hospitalized with Gastrointestinal Symptoms and Chronic Anxiety Disorder, Cardiovascular Innovations and Applications, 10.15212/CVIA.2021.0021, 6:1, (57-61) Singh T, Chapman A, Dweck M, Mills N and Newby D (2021) MINOCA: a heterogenous group of conditions associated with myocardial damage, Heart, 10.1136/heartjnl-2020-318269, 107:18, (1458-1464), Online publication date: 1-Sep-2021. Zenger B, Good W, Bergquist J, Rupp L, Perez M, Stoddard G, Sharma V and MacLeod R (2021) Pharmacological and simulated exercise cardiac stress tests produce different ischemic signatures in high-resolution experimental mapping studies, Journal of Electrocardiology, 10.1016/j.jelectrocard.2021.07.009, 68, (56-64), Online publication date: 1-Sep-2021. Pasupathy S and Beltrame J (2021) Refining the Role of CMR Imaging in MINOCA, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2021.03.024, 14:9, (1784-1786), Online publication date: 1-Sep-2021. Pelliccia F, Pepine C, Berry C and Camici P (2021) The role of a comprehensive two-step diagnostic evaluation to unravel the pathophysiology of MINOCA: A review, International Journal of Cardiology, 10.1016/j.ijcard.2021.05.045, 336, (1-7), Online publication date: 1-Aug-2021. Nicolau J, Feitosa G, Petriz J, Furtado R, Précoma D, Lemke W, Lopes R, Timerman A, Marin J, Bezerra L, Gomes B, Santos E, Piegas L, Soeiro A, Negri A, Franci A, Markman B, Baccaro B, Montenegro C, Rochitte C, Barbosa C, Virgens C, Stefanini E, Manenti E, Lima F, Monteiro F, Correa H, Pena H, Pinto I, Falcão J, Sena J, Peixoto J, Souza J, Silva L, Maia L, Ohe L, Baracioli L, Dallan L, Dallan L, Mattos L, Bodanese L, Ritt L, Canesin M, Rivas M, Franken M, Magalhães M, Oliveira M, Filgueiras N, Dutra O, Coelho O, Leães P, Rossi P, Soares P, Lemos P, Farsky P, Cavalcanti R, Alves R, Kalil R, Esporcatte R, Marino R, Giraldez R, Meneghelo R, Lima R, Ramos R, Falcão S, Dalçóquio T, Lemke V, Chalela W and Mathias W (2021)(2021)(2021)(2021) Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021, Arquivos Brasileiros de Cardiologia, 10.36660/abc.20210180, 117:1, (181-264), Online publication date: 15-Jul-2021., Online publication date: 15-Jul-2021., Online publication date: 1-Jul-2021., Online publication date: 1-Jul-2021. Luis S, Luis C, Habibian M, Lwin M, Gadowski T, Chan J, Hamilton-Craig C and Raffel O (2021) Prognostic Value of Cardiac Magnetic Resonance Imaging in Acute Coronary Syndrome Patients With Troponin Elevation and Nonobstructive Coronary Arteries, Mayo Clinic Proceedings, 10.1016/j.mayocp.2020.11.026, 96:7, (1822-1834), Online publication date: 1-Jul-2021. King O, Sunyovszki I and Terracciano C (2021) Vascularisation of pluripotent stem cell–derived myocardium: biomechanical insights for physiological relevance in cardiac tissue engineering, Pflügers Archiv - European Journal of Physiology, 10.1007/s00424-021-02557-8, 473:7, (1117-1136), Online publication date: 1-Jul-2021. Carvalho P, Caçoilo M, Afreixo V, Bastos J, Ferraz L, Vieira M, Santos L, Gonzaga A, Ferreira R, Adrega T, Faustino A and Briosa A (2021)(2021) Acute Myocardial Infarction with Non-Obstructive Coronary Arteries – Stratifying the Risk of a "new" Clinical Entity using an "Old" Tool, International Journal of Cardiovascular Sciences, 10.36660/ijcs.20190218, Online publication date: 30-Jun-2021., Online publication date: 30-Jun-2021. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D and Siontis G (2021) Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST, Revista Española de Cardiología, 10.1016/j.recesp.2020.12.024, 74:6, (544.e1-544.e73), Online publication date: 1-Jun-2021. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D, Siontis G, Kastrati A, Mamas M, Aboyans V, Angiolillo D, Bueno H, Bugiardini R, Byrne R, Castelletti S, Chieffo A, Cornelissen V, Crea F, Delgado V, Drexel H, Gierlotka M, Halvorsen S, Haugaa K, Jankowska E, Katus H, Kinnaird T, Kluin J, Kunadian V, Landmesser U, Leclercq C, Lettino M, Meinila L, Mylotte D, Ndrepepa G, Omerovic E, Pedretti R, Petersen S, Petronio A, Pontone G, Popescu B, Potpara T, Ray K, Luciano F, Richter D, Shlyakhto E, Simpson I, Sousa-Uva M, Storey R, Touyz R, Valgimigli M, Vranckx P, Yeh R, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D and Siontis G (2020) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, European Heart Journal, 10.1093/eurheartj/ehaa575, 42:14, (1289-1367), Online publication date: 7-Apr-2021. Dugani S, Fabbri M, Chamberlain A, Bielinski S, Weston S, Manemann S, Jiang R and Roger V (2021) Premature Myocardial Infarction: A Community Study, Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 10.1016/j.m
Referência(s)